Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study Group Indolent Lymphomas. Rummel M, et al. Among authors: hinke a. Lancet Oncol. 2016 Jan;17(1):57-66. doi: 10.1016/S1470-2045(15)00447-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26655425 Clinical Trial.
Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.
Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C, Werner C, Ziske C, Kirchner H, Metzner B, Souchon R, Ruffert U, Schütt G, Pollmanns A, Schmoll HJ, Middecke C, Baltzer J, Schrader I, Wiebringhaus H, Ko Y, Rösel S, Schwenzer T, Wernet P, Hinke A, Bender HG, Frick M; West German Study Group. Nitz UA, et al. Among authors: hinke a. Lancet. 2005 Dec 3;366(9501):1935-44. doi: 10.1016/S0140-6736(05)67784-7. Lancet. 2005. PMID: 16325695 Clinical Trial.
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. Heinemann V, et al. Among authors: hinke a. J Clin Oncol. 2006 Aug 20;24(24):3946-52. doi: 10.1200/JCO.2005.05.1490. J Clin Oncol. 2006. PMID: 16921047 Clinical Trial.
Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer.
Frickhofen N, Berdel WE, Opri F, Haas R, Schneeweiss A, Sandherr M, Kuhn W, Hossfeld DK, Thomssen C, Heimpel H, Kreienberg R, Hinke A, Möbus V; German Study Groups Arbeitsgemeinschaft Internistische Onkologie (AIO); Arbeitsgemeinschaft Gynäkologische Onkologie (AGO). Frickhofen N, et al. Among authors: hinke a. Bone Marrow Transplant. 2006 Oct;38(7):493-9. doi: 10.1038/sj.bmt.1705472. Epub 2006 Aug 21. Bone Marrow Transplant. 2006. PMID: 16980997 Clinical Trial.
Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA; AGO-Ovar/AIO; EBMT. Möbus V, et al. Among authors: hinke a. J Clin Oncol. 2007 Sep 20;25(27):4187-93. doi: 10.1200/JCO.2006.09.7527. Epub 2007 Aug 13. J Clin Oncol. 2007. PMID: 17698804 Clinical Trial.
Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.
Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P. Blohmer JU, et al. Among authors: hinke a. J Clin Oncol. 2011 Oct 1;29(28):3791-7. doi: 10.1200/JCO.2010.30.4899. Epub 2011 Aug 22. J Clin Oncol. 2011. PMID: 21860000 Clinical Trial.
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Giessen C, von Weikersthal LF, Hinke A, Stintzing S, Kullmann F, Vehling-Kaiser U, Mayerle J, Bangerter M, Denzlinger C, Sieber M, Teschendorf C, Freiberg-Richter J, Schulz C, Modest DP, Moosmann N, Aubele P, Heinemann V. Giessen C, et al. Among authors: hinke a. BMC Cancer. 2011 Aug 23;11:367. doi: 10.1186/1471-2407-11-367. BMC Cancer. 2011. PMID: 21861888 Free PMC article. Clinical Trial.
123 results